

## Harris & Harris Group Notes Article on OpGen in Technology Review

NEW YORK, June 22, 2012 (GLOBE NEWSWIRE) -- Harris & Harris Group, Inc. (Nasdaq:TINY), an early-stage, active investor in transformative nanotechnology companies, notes an article published today in Technology Review that discusses one of its portfolio companies, OpGen, Inc., and the potential benefits of OpGen's optical mapping technology in identification of food-borne illnesses and the study of human diseases, including cancer.

The article highlights OpGen's optical mapping technology that can reveal repeated sequences and other structural variations in a genome that high-throughput sequencing technologies can miss. In analyzing the sequence data generated by those technologies, pieces of identical sequence can be mistakenly assumed to come from the same spot in the chromosome, so the final genome sequence does not reflect as many copies as the chromosome really contains. Because optical mapping measures the true length of chromosomes, genome scientists can determine the true structure and map of the genome of interest. The article can be viewed at <a href="http://www.technologyreview.com/news/428283/a-map-of-the-whole-genome-tracks-outbreaks/">http://www.technologyreview.com/news/428283/a-map-of-the-whole-genome-tracks-outbreaks/</a>.

This press release may contain statements of a forward-looking nature relating to future events. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company's current beliefs, and a number of important factors could cause actual results to differ materially from those expressed in this press release. Please see the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2011, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company's business, including, but not limited to, the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company's actual results. Except as otherwise required by Federal securities laws, the Company undertakes no obligation to update or revise these forwardlooking statements to reflect new events or uncertainties. The references to the websites www.HHVC.com and www.technologyreview.com have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Harris & Harris Group is not responsible for the contents of third party websites.

CONTACT: Douglas W. Jamison TEL. NO. (212) 582-0900

Source: Harris & Harris Group